Ryeqo

October 25, 2022

Submission for Type II Variation Application for Ryeqo^® for the Treatment of Endometriosis

Read More

July 21, 2021

European Commission approves the commercialisation of Ryeqo^®

Gedeon Richter Plc. (‘Richter’) announces that the European Commission (‘EC’) has granted approval for the marketing authorisation of

Read More

April 30, 2021

Gedeon Richter and Myovant Sciences Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.

Myovant Sciences (NYSE:MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer

Read More